Search bioRxiv⌕ Search

Biology subjects

Mia, M.

Publications and source records attributed to Mia, M..

2 recordsLinked to original sources

Bioactivity Analysis of Secondary Metabolites from Actinomycetes' Isolated from Coastal Sediments

The rising threat of antibiotic resistance underscores the need for new antibiotics. Marine actinomycetes have emerged as promising sources of bioactive compounds. In this study, 22 isolates from marine sediments were morphologically identified, with nine confirmed as actinomycetes through 16S rRNA gene sequencing. Five strains- Streptomyces olivoverticillatus (T-2), Streptomyces cyaneus (T-4), Nocardiopsis synnemataformans (T-7), Streptomyces albogriseolus (T-8), and Streptomyces atrovirens (T-9)- exhibited significant antibacterial activity. Cultured in Starch Casein Broth, their metabolites were tested for antibacterial, antioxidant, anticoagulation, and anti-inflammatory activities. T-4 and T-8 demonstrated notable antimicrobial action, T-8 showing potent DPPH radical scavenging (372.09 {+/-} 11.05 {micro}g/mL). T-9 inhibited trypsin (IC50 435.12 {+/-} 15.88 {micro}g/mL) and had a prothrombin time of 12.08 {+/-} 1.46 minutes. T-8 enhanced RBC membrane stabilization (IC50 140.08 {+/-} 2.30 {micro}g/mL). These findings suggest that marine sediment-derived actinomycetes hold significant therapeutic potential and warrant further study.

microbiology↗

Computational screening of potential AT1R inhibitors from Nigella sativa for diabetic-hypertensive therapy

Hypertension, frequently coexists with Type 2 diabetes mellitus, causes due to Angiotensin II. Inhibiting Angiotensin II by targeting AT1R can potentially improve hypertension-related complications in patients with T2DM. In this study, we perform an in-silico screening based on molecular docking and molecular dynamic of 305 compounds of Nigella sativa against Angiotensin-II Type1 Receptor (AT1R). Molecular docking studies were conducted to investigate the binding affinities of the selected ligands with the target receptor and compared against the Losartan (control drug). Top 5 ligands were selected based on binding affinity. Subsequently, we conducted an ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling to assess their pharmacokinetic and safety profiles. Our findings revealed two promising ligands Beta-amyrin (CID-73145) and Taraxerol (CID-92097), which exhibited strong binding affinities and favorable pharmacological profiles with no signs of acute toxicity. The molecular dynamic simulations (MD) including RMSD, RMSF, and MMGBSA binding free energy results showed that selected two ligands bind to AT1R more proficiently with good stability over 100 ns. The computational study serves as a foundational basis for subsequent laboratory and clinical research aimed at identifying selective, potent, and less toxic diabetic-hypertensive therapy targeting AT1R. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=110 SRC="FIGDIR/small/610463v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@1b3fdf8org.highwire.dtl.DTLVardef@1e6dafforg.highwire.dtl.DTLVardef@133afd0org.highwire.dtl.DTLVardef@5b93c4_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioinformatics↗